Emerging Therapies for Inflammatory Bowel Disease

Roni Weisshof, Katia El Jurdi, Nada Zmeter, David T. Rubin

Research output: Contribution to journalReview articlepeer-review

75 Scopus citations


Inflammatory bowel disease (IBD) is a chronic heterogeneous group of diseases that has undergone major advances in the understanding of its etiology and pathogenesis in recent years. The development of biologics had resulted in better overall management of the disease, including lower rates of surgery and better long-term clinical and patient-reported outcomes. Treatment modalities have either been newly developed or extrapolated from their approved use for a different indication. Modes of action and treatment targets have varied as well. Treatments such as vedolizumab and ustekinumab, as well as second-generation corticosteroids have been approved by the US Food and Drug Administration (FDA) for the treatment of IBD. Other agents are currently being developed at various stages of clinical trials including anti-adhesion agents such as etrolizumab and abrilumab, JAK inhibitors such as tofacitinib, and anti-trafficking molecules. Toll-like receptors and phosphatidylcholine are also new promising emerging targets that are being investigated in phase 3 clinical trials. It is projected that many therapies will become available in the coming years if supported by the results of current clinical trials. This will provide IBD patients with a wide array of options and allow physicians to choose the best therapies for each individual patient.

Original languageEnglish
Pages (from-to)1746-1762
Number of pages17
JournalAdvances in Therapy
Issue number11
StatePublished - Nov 1 2018


  • Crohn’s disease
  • Inflammatory bowel disease
  • Therapy
  • Ulcerative colitis


Dive into the research topics of 'Emerging Therapies for Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this